Blog

Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy – Nature.com


Nature.com

Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy
Nature.com
“Taken together, these findings suggest that chromatin dysregulation may be a new avenue towards understanding why patients with ccRCC (and other types of cancer) respond to ICB,” says Van Allen. “This discovery warrants further experimental and

and more »

2018-01-22 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.